Covaxin production to be temporarily slowed down 'foreseeing decrease in demand'

Published on Apr 02, 2022 06:58 AM IST

In a statement, the vaccine manufacturer said: “For the coming period, the company will focus on pending facility maintenance, process and facility optimization activities.

Covaxin got the WHO's approval for emergency use last year. ((PIC FOR REPRESENTATION))
Covaxin got the WHO's approval for emergency use last year. ((PIC FOR REPRESENTATION))
By | Edited by Swati Bhasin

The production of Covaxin will be "temporarily slowed down", the Bharat Biotech said in a late-night statement on Friday as the vaccine maker further insisted it has "completed its supply obligations to procurement agencies," and it foresees a "decrease in demand". India has been reporting a fall in infections with less than 2,000 cases reported a day in the last two weeks. However, some countries have been witnessing a daily Covid surge driven by the BA.2 Omicron variant.

In a statement, the vaccine manufacturer said: “For the coming period, the company will focus on pending facility maintenance, process and facility optimization activities. As all existing facilities were repurposed for the manufacture of Covaxin, with continuous production during the past year, to meet the public health emergency of COVID-19, these upgrades were due."

It further pointed out that Covaxin, India's homegrown vaccine against Covid, is currently under the WHO's Emergency Use Listing or EUL.

"The company was also pleased to learn from the WHO, that the necessary optimisation work 'does not indicate a change in the risk-benefit ratio (for Covaxin) and the data, available to WHO, indicates the vaccine is effective and no safety concern exists'," the statement read.

The vaccine manufaturer is "working on further improvements and upgrades to ensure that the production of Covaxin continues to meet ever increasing global regulatory requirements," it said. "More than 1 million doses of Covaxin were introduced under clinical trial mode, where safety of subjects was actively documented. Finally, Covaxin was extensively evaluated in around 30,000 subjects in more than 10 controlled clinical trials, resulting in more than 15 publications," Bhrat Biotech added.

Covaxin got the WHO's nod last year. It is one of the two major vaccines that are being administered in India apart from the Serum Institute's Covishield.

Get Latest India Newsalong with Latest Newsand Top Headlinesfrom India and around the world.
SHARE THIS ARTICLE ON
  • ABOUT THE AUTHOR

    A newsroom junkie with 11+ years of experience with print and online publications; travel and books are the soup for the soul.

SHARE
Story Saved
×
Saved Articles
Following
My Reads
My Offers
Sign out
New Delhi 0C
Thursday, December 08, 2022
Start 15 Days Free Trial Subscribe Now
Register Free and get Exciting Deals